Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 2
2005 2
2006 5
2008 2
2009 3
2010 2
2011 4
2012 3
2013 5
2016 4
2017 3
2018 4
2019 2
2020 1
2021 1
2022 4
2023 4
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Yuan F, et al. Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7. Curr Med Res Opin. 2017. PMID: 28166427
Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS have shown inconsistent findings. ...
Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IB …
Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Brenner DM, Chey WD. Brenner DM, et al. Rev Gastroenterol Disord. 2009 Winter;9(1):7-15. Rev Gastroenterol Disord. 2009. PMID: 19367213 Review.
Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are strain specific. Bifidobacterium infantis 35624 ( B infantis 35624; Bifantis, The Procter & Gamble Company, Cincinn …
Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are …
Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome.
Cruchet Muñoz S, Verbeke Palma S, Lera Marqués L, Espinosa Pizarro MN, Malig Mechasqui J, Sorensen K. Cruchet Muñoz S, et al. Nutrients. 2024 Jun 20;16(12):1967. doi: 10.3390/nu16121967. Nutrients. 2024. PMID: 38931319 Free PMC article.
Irritable bowel syndrome (IBS) and vitamin D deficiency are common among children in Latin America. Previous studies show that Bifidobacterium longum35624(TM) improves IBS symptoms in adults. This real-world, single-arm, open-label study conducted in Chile investigated the …
Irritable bowel syndrome (IBS) and vitamin D deficiency are common among children in Latin America. Previous studies show that Bifidobact …
An Exopolysaccharide Produced by Bifidobacterium longum 35624 Inhibits Osteoclast Formation via a TLR2-Dependent Mechanism.
Wallimann A, Hildebrand M, Groeger D, Stanic B, Akdis CA, Zeiter S, Richards RG, Moriarty TF, O'Mahony L, Thompson K. Wallimann A, et al. Calcif Tissue Int. 2021 May;108(5):654-666. doi: 10.1007/s00223-020-00790-4. Epub 2021 Jan 3. Calcif Tissue Int. 2021. PMID: 33388801
The probiotic Bifidobacterium longum subsp. longum 35624 (B. longum 35624), with its surface exopolysaccharide (EPS624), has previously been demonstrated to induce immunoregulatory responses in the host and may, therefore, be a novel approach to prevent bone …
The probiotic Bifidobacterium longum subsp. longum 35624 (B. longum 35624), with its surface exopolysaccharide (EPS624) …
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.
Sabaté JM, Iglicki F. Sabaté JM, et al. World J Gastroenterol. 2022 Feb 21;28(7):732-744. doi: 10.3748/wjg.v28.i7.732. World J Gastroenterol. 2022. PMID: 35317278 Free PMC article.
BACKGROUND: Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with placebo in double-blind randomized studies. ...CONCLUSION: Thirty days of treatment with B. longum 35624 reduces disease severity an …
BACKGROUND: Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with …
Fecal bacterial microbiota in constipated patients before and after eight weeks of daily Bifidobacterium infantis 35624 administration.
Amieva-Balmori M, García-Mazcorro JF, Martínez-Conejo A, Hernández-Ramírez GA, García-Zermeño KR, Rodríguez-Aguilera O, Aja-Cadena M, Barradas-Cortés M, Quigley EMM, Remes-Troche JM. Amieva-Balmori M, et al. Rev Gastroenterol Mex (Engl Ed). 2023 Oct-Dec;88(4):369-380. doi: 10.1016/j.rgmxen.2022.06.014. Epub 2022 Jul 7. Rev Gastroenterol Mex (Engl Ed). 2023. PMID: 35810091 Free article.
INTRODUCTION AND AIM: In recent years, probiotics have been used in functional gastrointestinal disorders, including chronic constipation (CC). The effect of Bifidobacterium infantis strain 35624 on the gut microbiota of CC patients has not been previously studied. …
INTRODUCTION AND AIM: In recent years, probiotics have been used in functional gastrointestinal disorders, including chronic constipation (C …
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Groeger D, et al. Gut Microbes. 2013 Jul-Aug;4(4):325-39. doi: 10.4161/gmic.25487. Epub 2013 Jun 21. Gut Microbes. 2013. PMID: 23842110 Free PMC article. Clinical Trial.
Certain therapeutic microbes, including Bifidobacteria infantis (B. infantis) 35624 exert beneficial immunoregulatory effects by mimicking commensal-immune interactions; however, the value of these effects in patients with non-gastrointestinal inflammatory conditions remai …
Certain therapeutic microbes, including Bifidobacteria infantis (B. infantis) 35624 exert beneficial immunoregulatory effects by mimi …
Probiotic treatment (Bifidobacterium longum subsp. longum 35624) affects stress responsivity in male rats after chronic corticosterone exposure.
Haas GS, Wang W, Saffar M, Mooney-Leber SM, Brummelte S. Haas GS, et al. Behav Brain Res. 2020 Sep 1;393:112718. doi: 10.1016/j.bbr.2020.112718. Epub 2020 May 30. Behav Brain Res. 2020. PMID: 32485204
Therefore, the current study investigates the effects of chronic administration of the commercially available probiotic Bifidobacterium longum subsp. longum 35624(B. 35624) to male and female rats under control or "stressed" conditions. ...Rats were sacrifice …
Therefore, the current study investigates the effects of chronic administration of the commercially available probiotic Bifidobacterium …
Exopolysaccharide from Bifidobacterium longum subsp. longum 35624 modulates murine allergic airway responses.
Schiavi E, Plattner S, Rodriguez-Perez N, Barcik W, Frei R, Ferstl R, Kurnik-Lucka M, Groeger D, Grant R, Roper J, Altmann F, van Sinderen D, Akdis CA, O'Mahony L. Schiavi E, et al. Benef Microbes. 2018 Sep 18;9(5):761-773. doi: 10.3920/BM2017.0180. Epub 2018 May 4. Benef Microbes. 2018. PMID: 29726281
We recently described that the loss of an exopolysaccharide (EPS) from Bifidobacterium longum 35624 eliminated its protective effects in colitis and respiratory allergy murine models. Our goal was to investigate the immune response to purified EPS from B. longum …
We recently described that the loss of an exopolysaccharide (EPS) from Bifidobacterium longum 35624 eliminated its protective …
50 results